Analysis of the therapeutic efficacy of octreotide combined with terlipressin in hepatorenal syndrome with decompensated liver cirrhosis

Abstract

Abstract: Objective To summarize the clinical data of patients with decompensated liver cirrhosis complicated with hepatorenal syndrome (HRS), and to investigate the efficacy of octreotide plus terlipressin in the treatment of these patients.Methods From February 2015 to November 2019, 92 patients with decompensated cirrhosis complicated with HRS were treated in our hospital. The average age was (50.4 ± 9.8) years. Patients who met the diagnostic criteria of decompensated liver cirrhosis and HRS-related diseases were included. They were randomly divided into an observation group (n=46) and a control group (n=46). The control group was treated with terlipressin, and the observation group was treated with terlipressin and octreotide at the same time. The measurement data were presented as (±s), and analyzed by t-test; the counting data were expressed as percentages (%), and analyzed by chi-square test.Results The average 24-hour urine output of the observation group [(1 050.6 ± 325.4) mL] after treatment was significantly higher than that of the control group [(687.0 ± 248.5) mL, P=0.002]. And the average weight of the observation group [(54.0 ± 4.2) kg] after treatment was significantly lower than that of the control group [(58.7 ± 6.0) kg, P=0.038]. There were no significant differences in age, sex, Child-Pugh grade and etiology of liver cirrhosis between the 2 groups (P>0.05). There were significant differences in total bilirubin, direct bilirubin, albumin, urea nitrogen, creatinine and sodium ions before and after treatment in 2 groups (all P<0.05). After treatment, the total bilirubin and urea nitrogen in the observation group [(14.0 ± 11.2) μmol/L, (11.3 ± 3.0) mmol/L] were significantly lower than those in the control group [(21.4 ± 13.2) μmol/L, (15.4 ± 5.2) mmol/L, both P<0.05]. The albumin in the observation group [(33.4 ± 6.8) g/L] was significantly higher than that in the control group [(29.4 ± 8.1) g/L, P<0.05]. However, there was no significant difference in posttreatment direct bilirubin, creatinine and sodium ions between the 2 groups (P>0.05).Conclusion Octreotide combined with terlipressin in the treatment of decompensated liver cirrhosis complicated with HRS can increase urine volume and albumin, reduce body weight, the production of total bilirubin and urea nitrogen.

Key words: Liver cirrhosis, Hepatorenal syndrome, Terlipressin, Octreotide

HU Zhang-chao, BAI Xue, CHENG Shuai-shi, AN Jun-li. Analysis of the therapeutic efficacy of octreotide combined with terlipressin in hepatorenal syndrome with decompensated liver cirrhosis[J]. Chinese Hepatolgy, 2020, 25(12): 1294-1296.

References

[1] Wang H, Liu A, Bo W, et al. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis. Medicine (Baltimore), 2018, 97:e0431.
[2] Amin AA, Alabsawy EI, Jalan R, et al. Epidemiology, pathophysiology, and management of hepatorenal syndrome. Semin Nephrol, 2019, 39:17-30.
[3] Allegretti AS, Israelsen M, Krag A, et al. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. Cochrane Database Syst Rev, 2017, 6:CD005162.
[4] Facciorusso A, Chandar AK, Murad MH, et al. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol, 2017, 2:94-102.
[5] Salerno F, Gerbes A, Ginès P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut, 2007, 56:1310-1318.
[6] Salerno F, Navickis RJ, Wilkes MM. Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis. BMC Gastroenterol, 2015, 15:167.
[7] Guo SB, Li Q, Duan ZJ, et al. Octreotide attenuates liver fibrosis by inhibiting hepatic heme oxygenase-1 expression. Mol Med Rep, 2015, 11:83-90.
[8] Wang X, Liu Y, Zhao J, et al. Clinical efficacy of octreotide acetate combined with thrombin in the treatment of liver cirrhosis complicated with gastrointestinal hemorrhage. Exp Ther Med, 2019, 17:3417-3422.
[9] Blasco-Perrin H, Bureau C. Management of patients with decompensated liver cirrhosis. Nat Rev Gastroenterol Hepatol, 2018, 15:753-764.
[10] Ginès P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet, 2003,362:1819- 1827.
[11] Best LM, Freeman SC, Sutton AJ, et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev, 2019, 9:CD013103.
[12] Arroyo V. Microalbuminuria, systemic inflammation, and multiorgan dysfunction in decompensated cirrhosis: evidence for a nonfunctional mechanism of hepatorenal syndrome. Hepatol Int, 2017, 11:242-244.
[13] Watany MM, Hagag RY, Okda HI. Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study. Clin Chem Lab Med, 2018, 56:739-747.
[14] Low G, Alexander GJ, Lomas DJ. Renal impairment in cirrhosis unrelated to hepatorenal syndrome. Can J Gastroenterol Hepatol, 2015, 29:253-257.
[15] Cavallin M, Fasolato S, Marenco S, et al. The treatment of hepatorenal syndrome. Dig Dis, 2015,33:548-554.
[16] Jain A, Gardner S, Chitturi S, et al. Octreotide as a bridge to definitive surgery in a patient with cirrhosis and a large spontaneous abdominal wall haematoma. Intern Med J, 2018 , 48:1273-1274.